Vitamin D (D3, cholecalciferol)

endocrine hormonalinflammation redox

Sold as a consumer product in 1 of 9 markets tracked; in clinical trials in 1.

1 randomized trial (85 people, 16 weeks). Of its 2 main endpoints, 1 improved, 1 showed no effect.

Evidence map

each mark is a study; size shows participants; hover, tap or focus for details

main endpoints improvedno effectworsenedmixedobservationalanother intervention, contextsize not reported

Higher rows are closer to a person taking this. A case that rests only on the lower rows rests on animals or cells.

What each study measured

outlined square: the main (primary) endpoint

Harms reported

human studies

Where it is available

by regulator; select a market for its source

If you are tracking this yourself

measures the human studies used, by how repeatable they are

Repeatability is whether the same person measured twice gets the same number. It is not statistical significance. It informs study or protocol design only, never advice for a person.

What would change this picture

each study's own statement

Trials under way

Every study (5)

T7 Aigner 2022 Effects of Vitamin D3 Supplementation and Resistance Training on Physical Performance in Community-Dwelling Older Adults with Vitamin D Insufficiency: A Randomized Controlled Trial doi:10.3390/nu14010086
T5 Larsson 2019 Serum 25-hydroxyvitamin D in amyotrophic lateral sclerosis: mendelian randomization study doi:10.1016/j.neurobiolaging.2019.10.024
T5 Bae 2026 Associations of Serum Testosterone and 25-Hydroxyvitamin D with Bone Mineral Density in Aging Men doi:10.5534/wjmh.260018
TX Rastmanesh 2021 Prediagnostic Serum 25-Hydroxyvitamin D and Mortality Among Bladder Cancer Patients in the Janus Serum Bank Cohort: A Short Comment [Letter] doi:10.2147/clep.s339834
TX Han 2019 25-Hydroxyvitamin D and Total Cancer Incidence and Mortality: A Meta-Analysis of Prospective Cohort Studies doi:10.3390/nu11102295